Method for producing modified oligonucleotide including complementary portion

The enzymatic condensation of oligonucleotide fragments using ligase addresses the inefficiencies of traditional synthesis methods, enabling high-purity production of modified oligonucleotides with complementary portions, particularly siRNA, by maintaining annealing ability and improving efficiency.

JP2024156907AInactive Publication Date: 2024-11-06AJINOMOTO CO INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024129867
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-09-25
Filing Date
2024-08-06
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing methods for producing oligonucleotides, such as siRNA, face challenges with decreased purity and yield as chain length increases, and there is a need for a more efficient method that can handle short and modified oligonucleotides with reduced annealing ability.

Method used

A method involving the enzymatic condensation of four or more oligonucleotide raw fragments using oligonucleotide ligase to produce modified oligonucleotides with complementary portions, optimizing conditions to maintain high purity and efficiency, even with short chain lengths and modified bases.

Benefits of technology

The method enables the efficient production of modified oligonucleotides with high purity, overcoming the limitations of traditional chemical synthesis by improving production efficiency and maintaining annealing ability despite short chain lengths and modifications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156907000018
    Figure 2024156907000018
  • Figure 2024156907000019
    Figure 2024156907000019
  • Figure 2024156907000020
    Figure 2024156907000020
Patent Text Reader

Abstract

To provide an efficient method for producing an oligonucleotide including a complementary portion such as siRNA and heteroduplex oligonucleotide.SOLUTION: More specifically, provided is a method for producing a modified oligonucleotide including a complementary portion of 11 to 27 base lengths, where the method includes treating the total of four or more oligonucleotide raw material fragments in the presence of oligonucleotide ligase to create the modified oligonucleotide, and the total of four or more oligonucleotide raw material fragments are equivalent to an oligonucleotide raw material fragment obtained in the case where the modified oligonucleotide is divided by a fragment connection part that satisfies the following conditions (i) to (v): (i) one or more fragment connection parts are present in each chain side of the complementary portion, and two or more fragment connection parts in total are present in the modified oligonucleotide; (ii) in the case where the modified oligonucleotide is divided by the fragment connection part, a protruding end is formed in the complementary portion, and the protruding end is 1 to 10 base lengths; (iii) at least one oligonucleotide raw material fragment includes a modified nucleotide; (iv) four oligonucleotide raw material fragments of the total of four or more oligonucleotide raw material fragments include a complementary portion of 5 to 25 base lengths; and (v) the total of base lengths equivalent to each chain side of the complementary portion of the oligonucleotide raw material fragments are severally 11 to 27 base lengths.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for making modified oligonucleotides that contain a complementary portion. [Background technology]

[0002] Oligonucleotides such as siRNA and antisense have been shown to be useful as nucleic acid medicines, and their development has been intensified in recent years. Oligonucleotides are mainly produced by synthesis, for example, by serially extending nucleotide residues one base at a time in solid-phase synthesis such as the phosphoramidite method. However, this method has problems such as a decrease in purity and yield of the product as the chain length of the oligonucleotide increases, and low production efficiency. Therefore, a parallel synthesis method is required in which oligonucleotides are synthesized as short fragments and then condensed to obtain the desired oligonucleotide.

[0003] Patent Document 1 describes a method for producing a single-stranded oligonucleotide by annealing a plurality of oligonucleotide raw material fragments corresponding to fragments obtained by dividing a target oligonucleotide with a template oligonucleotide complementary to the target oligonucleotide, enzymatically condensing the annealed oligonucleotide raw material fragments with each other, and separating the obtained target oligonucleotide strand from the template oligonucleotide. Non-Patent Document 1 describes PEGylation of oligo-DNA by linking the oligo-DNA fragment and the PEGylated oligo-DNA fragment at the sticky end with DNA ligase. However, since Non-Patent Document 1 only uses natural oligo-DNA fragments, it is unclear whether enzymatic condensation of oligo-DNA containing complementary portions is possible using oligo-DNA containing short chains and modified bases, which suggests a decrease in annealing ability, as raw materials. Non-Patent Documents 2 and 3 describe a method in which nicks formed by annealing one oligonucleotide strand to two complementary oligonucleotide starting fragments are ligated with a ligase. Non-Patent Document 4 describes the formation of a double-stranded RNA having a size of 48 mer or more by ligating 24-mer double-stranded oligo RNA having a sticky end with RNA ligase. However, in Non-Patent Document 4, since the substrate is 24 bases long and the product is 48 bases long, both are long, the reaction was carried out only under conditions where the annealing ability of the substrate is high, suggesting that the annealing ability is significantly reduced. Therefore, it was not known whether an enzyme reaction having two or more condensation points would proceed when using an oligonucleotide substrate that is short and is expected to reduce the ligation activity of the enzyme due to the introduction of modified bases, which suggests that the annealing ability is significantly reduced. Non-Patent Document 5 describes the synthetic production of siRNA. Non-Patent Document 6 describes that RNA ligase DraRnl belongs to the Rnl5 family. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] US Patent Application Publication No. 2018 / 0023122 [Non-patent literature]

[0005] [Non-Patent Document 1] Sosic A, Pasqualin M, Pasut G, Gatto B. 2014. Enzymatic formation of PEGylated oligonucleotides. Bioconjug Chem 25:433-441. [Non-Patent Document 2] Bullard, DR, & Bowater, RP (2006). Direct comparison of nick-joining activity of the nucleic acid ligases from bacteriophage T4. Biochem. J, 398, 135-144. [Non-Patent Document 3] Nandakumar, J., & Shuman, S. (2004). How an RNA Ligase Discriminates RNA versus DNA Damage. Molecular Cell, 16(2), 211-221. [Non-Patent Document 4] Nandakumar J, Ho CK, Lima CD, Shuman S. 2004. RNA substrate specificity and structure-guided mutational analysis of bacteriophage T4 RNA ligase 2. J Biol Chem 279:31337-31347. [Non-Patent Document 5] Jayaprakash K. Nair, et al. (2014), Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing. J. Am. Chem. Soc., 136, 16958-16961. [Non-Patent Document 6] MIHAELA-CARMEN UNCIULEAC and STEWART SHUMAN (2019),RNA 21:824-832 Summary of the Invention [Problem to be solved by the invention]

[0006] An object of the present invention is to provide an efficient method for producing oligonucleotides containing complementary portions, such as siRNAs and heteroduplex oligonucleotides. [Means for solving the problem]

[0007] As a result of extensive research, the present inventors have discovered that an oligonucleotide containing a complementary portion, such as a double-stranded oligonucleotide, can be directly constructed by treating, with oligonucleotide ligase, four or more oligonucleotide starting fragments corresponding to fragments obtained by dividing both complementary portions of an oligonucleotide containing a desired complementary portion, and that this can be produced with higher production efficiency and higher purity than tandem synthesis methods such as solid-phase synthesis, thereby completing the present invention.

[0008] Conventionally, relatively short double-stranded oligonucleotides such as siRNAs have been produced by chemical synthesis because chemical synthesis is easy and simple. Specifically, the two constituent oligonucleotide strands are each chemically synthesized (e.g., solid-phase synthesis), purified, and then both strands are annealed to produce them. Therefore, methods using enzymatic condensation have not been reported very often, and among them, the only enzymatic synthesis method reported is a method for producing a relatively long double-stranded oligonucleotide of 28 bases or more in length from four or more oligonucleotide raw fragments. The base length of the oligonucleotide raw fragment used in the production of a short oligonucleotide is naturally short, but it is thought that the annealing ability of the oligonucleotide raw fragment with a short base length is also reduced. It was also thought that the annealing ability would be further reduced if the constituent nucleotides were modified. Therefore, in the enzymatic oligonucleotide synthesis method using ligase, the annealing ability of the oligonucleotide raw fragment was considered to be important, so no attempt was made to produce a shorter oligonucleotide, such as an oligonucleotide less than 28 bases long, from four or more oligonucleotide raw fragments using ligase. However, after extensive research, the present inventors have unexpectedly found that, when ligase and four or more oligonucleotide raw material fragments are used, double-stranded oligonucleotides less than 28 bases long can be successfully produced without being affected by annealing ability. They also found that, in the case of short oligonucleotides, the purity of the produced oligonucleotides is improved, and have completed the present invention.

[0009] That is, the present invention is as follows. [1] A method for producing a modified oligonucleotide comprising a complementary portion having a length of 11 to 27 bases, comprising the steps of: The method comprises treating a total of four or more oligonucleotide starting fragments in the presence of an oligonucleotide ligase; The total of four or more oligonucleotide starting fragments correspond to the oligonucleotide starting fragments obtained by dividing the modified oligonucleotide at fragment linkages that satisfy the following conditions (i) to (v): (i) there is at least one fragment linker on each strand of the complementary portion, and there are a total of two or more fragment linkers in the modified oligonucleotide; (ii) when the modified oligonucleotide is split at the fragment junction, a protruding end is formed in the complementary portion, and the protruding end is 1 to 10 bases long; (iii) at least one oligonucleotide starting fragment contains a modified nucleotide; (iv) four of the four or more oligonucleotide raw material fragments contain a complementary portion having a length of 5 to 25 bases; and (v) The total length of bases corresponding to each strand of the complementary portion of the oligonucleotide starting fragment is 11 to 27 bases. The method according to [1], wherein the protruding end in [2](ii) is 2 to 6 bases long. [3] The method according to [1] or [2], wherein the complementary portions of the four oligonucleotide starting fragments defined in (iv) other than the protruding ends are 4 to 16 bases long. [4] Any of the methods according to [1] to [3], wherein the oligonucleotide ligase is an RNA ligase. [5] The method according to [4], wherein the oligonucleotide ligase is a double-stranded RNA ligase. [6] The method according to [5], wherein the double-stranded RNA ligase is an RNA ligase of the Rnl2 family or the Rnl5 family. [7] Any of the methods according to [1] to [6], wherein the modified oligonucleotide contains a modified nucleotide residue. [8] The method according to [7], wherein the modified nucleotide residue is a 1', 2', 3', or 4' chemically modified nucleotide residue, a 5'- or 3'-phosphate group modified nucleotide residue, a bridged modified nucleotide residue, a carrier-added modified nucleotide residue, or a sugar backbone-substituted nucleotide residue. [9] The modified nucleotide residue is i) the 1', 2', 3', or 4' position is C 1~6 Alkyloxy C 1~6 Alkylene, -OC 1~6 Alkyl, -OC 6~14 Aryl, -C-aryl, halogen atom, -OC 1~6 Alkyl N-amide C 1~6 Alkylene, -OC 1~6 Alkyl-(C 1~6 Alkyl-)amino-C 1~6 Alkylene, or -O-aminoC 1~6 a 1', 2', 3', or 4' chemically modified nucleotide residue substituted with alkyl (e.g., -O-aminopropyl, -O-AP); ii) 5'- or 3'-phosphate modified nucleotide residues in which the hydroxyl group is replaced by -O-Ρ(S)(OH)2, -NH-Ρ(O)(OH)2, or -NH-Ρ(S)(OH)2, which may be substituted by a protecting group; iii) The 2' and 4' sites are 2'-OC 1~6 Alkylene-4', 2'-O-ethylene-4', 2'-O-methyl substituted methylene-4', 2'-OC 1~6 Alkylene-OC 1~6 Alkylene-4',2'-ON(R)-C 1~6 Alkylene-4' (wherein R represents methyl, hydrogen or benzyl), 2'-N(R)-C(O)-4', 2'-NH-C 1~6 Alkylene-4' or 2'-C 1~6 or the 3' and 5' sites are substituted with 3'-C 1~6 an alkylene-5'-substituted bridged modified nucleotide residue; or iv) a hexitol nucleic acid (HNA) residue, a cyclohexenyl nucleic acid (CeNA) residue, or a morpholino nucleic acid (PMO) residue This is method (8).

[10] Any of the methods according to [1] to [9], wherein the total molar ratio of any two oligonucleotide starting fragments selected from a total of four or more oligonucleotide starting fragments is 0.5 to 2.

[11] Any of the methods according to [1] to

[10] , wherein the oligonucleotide starting material fragment is treated under a monovalent cation salt concentration of 10 mM or less.

[12] Any of the methods according to [1] to

[11] , wherein the mixed solution of oligonucleotide raw material fragments is not placed at a high temperature and then cooled down prior to the treatment.

[13] The method according to any one of [1] to

[12] , wherein production of impurities in the modified oligonucleotide is suppressed.

[14] Any of the methods according to [1] to

[13] , further comprising purifying the modified oligonucleotide. Effect of the Invention

[0010] According to the method of the present invention, modified oligonucleotides such as siRNAs and heteroduplex oligonucleotides can be efficiently produced with high purity. [Brief description of the drawings]

[0011] [Figure 1] FIG. 1 is a schematic diagram showing an example of the mechanism of the present invention. [Figure 2-1] Figures 2-1 to 2-6 are graphs showing the amount of siRNA produced depending on the concentration of T4 RNA ligase 2 when six patterns (combination numbers 1 to 6) of combinations of four short natural RNA fragments for producing the same siRNA in Example 1 were reacted with T4 RNA ligase 2. [Figure 2-2] 2-1 to 2-6 are as described above. [Figure 2-3] 2-1 to 2-6 are as described above. [Figure 2-4] 2-1 to 2-6 are as described above. [Figure 2-5] 2-1 to 2-6 are as described above. [Figure 2-6] 2-1 to 2-6 are as described above. [Figure 3-1] 3-1 to 3-4 are graphs showing the time course of the amount of siRNA produced at each reaction temperature when a combination of four short natural RNA fragments was reacted with T4 RNA ligase 2 in Example 2. FIG. [Figure 3-2] 3-1 to 3-4 are as described above. [Figure 3-3] 3-1 to 3-4 are as described above. [Diagram 3-4] 3-1 to 3-4 are as described above. [Figure 4] FIG. 4 shows the results of HPLC analysis of siRNA and oligonucleotide preparations produced from modified RNAs at each T4 RNA ligase 2 concentration in Example 3. [Diagram 5] FIG. 5 shows HPLC analysis charts of reaction products obtained without any enzyme and in the presence of Deinococcus radiodurans-derived RNA ligase (DraRnl) in Example 5, as well as RNA preparations (sense strand and antisense strand). [Figure 6] FIG. 6 is a schematic diagram of the reaction products in Example 6, and HPLC analysis charts of the reaction products in the absence of enzyme and in the presence of T4 RNA ligase 2. [Figure 7] FIG. 7 shows the relationship between four oligonucleotide starting fragments (including an oligonucleotide starting fragment containing a mismatched base pair) and the double-stranded modified oligonucleotide produced therefrom. [Figure 8] FIG. 8 shows the relationship between five or six oligonucleotide starting fragments and the double-stranded modified oligonucleotides produced therefrom. [Figure 9]FIG. 9 shows the confirmation by HPLC analysis of the production of double-stranded modified oligonucleotides in reactions using five or six oligonucleotide starting fragments. [Figure 10] FIG. 10 shows the relationship between four oligonucleotide starting fragments, including an oligonucleotide starting fragment having a DMTr group added to its 5' end, and a double-stranded modified oligonucleotide produced therefrom. [Figure 11] FIG. 11 shows the relationship between four oligonucleotide starting fragments, including an oligonucleotide starting fragment having a carrier added to its 5' end, and the double-stranded modified oligonucleotide produced therefrom. [Figure 12] FIG. 12 shows the relationship between four oligonucleotide starting fragments in which the phosphate groups at the linkages of the nucleotide residues have been replaced with thiophosphate groups, and the double-stranded modified oligonucleotides produced therefrom. [Figure 13] FIG. 13 shows the relationship between the four oligonucleotide starting fragments and the hairpin-shaped modified oligonucleotides produced therefrom. [Figure 14] Figure 14 shows the relationship between four oligonucleotide raw material fragments used to compare the effect of the base length of the protruding end of the oligonucleotide raw material fragment on reactivity and the double-stranded modified oligonucleotides produced from them. [Figure 15] FIG. 15 shows the relationship between four oligonucleotide starting fragments used for comparing the effect of the base length of the product on reactivity and the double-stranded modified oligonucleotides produced therefrom. [Figure 16] FIG. 16 shows the relationship between the four oligonucleotide starting fragments used to examine the initial reaction rate at high substrate concentrations and the double-stranded modified oligonucleotides produced therefrom. [Figure 17] FIG. 17 shows the relationship between the four oligonucleotide starting fragments used for comparing the base lengths of the products and the double-stranded modified oligonucleotides produced therefrom. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] (Summary of the Invention) The present invention will be described below. In order to facilitate the description of the present invention, an example of the mechanism of the present invention is shown in the schematic diagram of Figure 1. However, this schematic diagram is merely an example for describing the present invention, and does not limit the present invention.

[0013] The present invention provides a method for producing a modified oligonucleotide containing a complementary portion having a length of 11 to 27 bases (hereinafter, may be referred to as "target modified oligonucleotide" or the like). The method of the present invention involves treating a total of four or more oligonucleotide starting fragments as raw materials in the presence of an oligonucleotide ligase to produce a target modified oligonucleotide. The target modified oligonucleotide produced by the method of the present invention, the oligonucleotide starting fragments and oligonucleotide ligase used in the method of the present invention, and each of the treatment conditions for carrying out the method of the present invention will be described in detail below.

[0014] (the modified oligonucleotide of interest) The desired modified oligonucleotide produced by the method of the present invention is a modified oligonucleotide that contains a complementary portion having a length of 11 to 27 bases.

[0015] "Oligonucleotide" refers to an oligomer containing nucleotide residues as monomer units. Examples of "oligonucleotide" include oligo-RNA, oligo-DNA, and RNA-DNA hybrid oligonucleotides.

[0016] Oligonucleotides can be classified into "natural oligonucleotides" and "modified oligonucleotides." "Natural oligonucleotides" refer to oligonucleotides composed of nucleotide residues (adenosine (A), guanosine (G), cytidine (C), uridine (U), deoxyadenosine (dA), deoxyguanosine (dG), deoxycytidine (dC), thymidine (dT), hereinafter referred to as "natural nucleotide residues") that constitute polynucleotides (RNA and DNA) contained in cells. "Modified oligonucleotides" refer to oligonucleotides other than "natural oligonucleotides" and contain components other than natural nucleotide residues (hereinafter referred to as "modified residues"). Modified residues include, for example, modified nucleotide residues, amino acid residues, and linkers. Modified nucleotide residues include, for example, nucleotide residues containing the modifications described below. Amino acids include amino acid derivatives. Examples of amino acids include glycine, alanine, valine, leucine, isoleucine, proline, methionine, phenylalanine, tryptophan, serine, threonine, asparagine, glutamine, tyrosine, cysteine, aspartic acid, glutamic acid, histidine, lysine, arginine, and derivatives thereof. An amino acid derivative refers to an amino acid in which any atom or group in the amino acid is replaced with another atom or group, such as an amino acid in which a hydrogen atom in an amino group, a hydrogen atom in a carboxyl group, an oxygen atom, a hydroxyl group, any atom or group in a side chain, or a hydrogen atom bonded to a backbone carbon atom (e.g., α-, β-, γ-, δ-carbon atom) is replaced with another atom (e.g., a halogen atom such as a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom) or group (e.g., a substituent after substitution in a chemical modification described below).

[0017] The "modification" in "modified nucleotide residue" includes substitution of a substituent in the sugar moiety (ribose or deoxyribose) of the nucleotide residue, substitution of the sugar moiety itself (sugar backbone) of the nucleotide residue, and modification of the nucleobase moiety of the nucleotide residue (e.g., substitution of a substituent in the nucleobase moiety).

[0018] Examples of "substituents of the sugar moiety of a nucleotide residue" include substitutions of 1'-H, 2'-OH (only ribose), 2'-H, 3'-OH, 3'-NH2, 3'-H, 3'-phosphate group, 4'-H, 5'-phosphate group, or combinations thereof. Here, "phosphate group" includes not only -OP(O)(OH)2, but also groups in which an oxygen atom is replaced with a sulfur atom or ΝH (e.g., -O-Ρ(S)(OH)2, -NH-Ρ(O)(OH)2, -NH-Ρ(S)(OH)2). In addition, when the hydroxyl group (-OH) in a phosphate group is OR * (In the formula, R * represents an organic group such as a protecting group for a phosphate group) (e.g., a protected phosphate group). Examples of such substitutions include 1', 2', 3', or 4'-chemical modifications (substitution of the 1', 2', 3', or 4' position with another substituent), 5'- or 3'-phosphate group modifications (substitution of the 5'- or 3'-phosphate group with another substituent), bridged modifications (substitution that bridges two of the 1', 2', 3', or 4' positions), and carrier-added modifications (substitution of the 1', 2', 3', or 4' position with a carrier).

[0019] The chemical modification may be introduced, for example, to improve the degradation resistance of the oligonucleotide. Substituents after substitution in the chemical modification include, for example, C 1~6 Alkyloxy C 1~6 Alkylene (e.g., methoxyethyl: MOE), -OC 1~6 Alkyl (e.g., -O-Me), -OC 6~14 Aryl (e.g., -O-phenyl), -C-aryl (e.g., -C-phenyl), halogen atom (e.g., fluorine atom), -OC 1~6 Alkyl N-amide C 1~6 Alkylene (e.g., -ON-methylacetamide, -O-NMA), -OC 1~6 Alkyl-(C 1~6 Alkyl-)amino-C 1~6 Alkylene (e.g., -O-dimethylaminoethoxyethyl, -O-DMAEOE), and -O-aminoC 1~6Examples of the chemical modification include alkyl (e.g., -O-aminopropyl, -O-AP). The chemical modification is preferably a 2'-chemical modification (substitution at the 2' site) or a 3'-chemical modification (substitution at the 3' site), and among these, the 2'-chemical modification (substitution at the 2' site) is more preferred. Examples of the substituent after the substitution in the 2'-chemical modification include 2'-C 1~6 Alkyloxy C 1~6 Alkylene (e.g., 2'-methoxyethyl), 2'-OC 1~6 Alkyl (e.g., 2'-O-Me), 2'-OC 6~14 Aryl (e.g., 2'-O-phenyl), 2'-C-aryl (e.g., 2'-C-phenyl), 2'-halogen atom (e.g., 2'-F), 2'-OC 1~6 Alkyl N-amide C 1~6 Alkylene (e.g., 2'-ON-methylacetamide, 2'-O-NMA), 2'-OC 1~6 Alkyl-(C 1~6 Alkyl-)amino-C 1~6 Alkylene (e.g., 2'-O-dimethylaminoethoxyethyl, 2'-O-DMAEOE), and 2'-O-amino C 1~6 Alkyl (e.g., 2'-O-aminopropyl, 2'-O-AP) is included. Substituents after substitution in 3'-chemical modification include, for example, 3'-OP(O)(OH). 2、 3'-O-Ρ(S)(OH)2, 3'-NH-Ρ(O)(OH)2, 3'-NH-Ρ(S)(OH)2), and the hydroxyl group (-OH) in the phosphate group are OR * (In the formula, R * represents an organic group such as a protecting group for a phosphate group, as described below.

[0020] The 5'- or 3'-phosphate group modification may be introduced, for example, to improve the resistance of the oligonucleotide to degradation. Examples of the 5'- or 3'-phosphate group modification include the substitution of a phosphate group (-OP(O)(OH)2) with a group in which the oxygen atom in the phosphate group is replaced with a sulfur atom or ΝH. Examples of such groups include -O-Ρ(S)(OH)2 (thiophosphate group: phosphorothioate type modification), -NH-Ρ(O)(OH)2, and -NH-Ρ(S)(OH)2. In addition, the 5'- or 3'-phosphate group modification includes the substitution of a hydroxyl group (-OH) in the phosphate group with an OR * (In the formula, R * represents an organic group such as a protecting group for a phosphate group) (e.g., a protected phosphate group). Examples of the protecting group for a phosphate group include a trityl (Tr) group, a p-methoxyphenyldiphenylmethyl (MMTr) group, a di(p-methoxyphenyl)phenylmethyl (DMTr) group, and a cyanoethyl group (CN-C2H4-).

[0021] The bridging modification may be introduced, for example, to improve the conformational stability of a nucleotide residue. Examples of the bridging modification include 2'4'-bridging modification (substitution that bridges 2'-OH and 4'-H), 3'5'-bridging modification (substitution that bridges 3'-H and 5'-H), etc. Examples of the 2'4'-bridging modification include 2'-OC of 2'-OH and 4'-H. 1~6 Substitution with alkylene-4' (e.g., 2'-O-methylene-4' (locked nucleic acid: LNA), 2'-O-ethylene-4' (ethylene-bridged nucleic acid: ENA), substitution with 2'-O-methyl-substituted methylene-4' (constrained ethyl-bridged nucleic acid: a type of BNA (cEt-BNA)), 2'-OH and 4'-H in 2'-OC 1~6 Alkylene-OC 1~6 Substitution with alkylene-4' (e.g., 2'-O-methylene-O-methylene-4' (Bridged nucleic acid: a type of BNA (BNA COC )), 2'-OH and 4'-H 2'-ON(R)-C 1~6 Substitution with alkylene-4' (e.g., 2'-ON(R)-methylene-4' (Bridged nucleic acid: a type of BNA (BNA NC), where R represents methyl, hydrogen atom or benzyl), replacement of 2'-NH2 and 4'-H with 2'-N(R)-C(O)-4' (e.g., 2'-N(methyl)-C(O)-4' (amide bridged nucleic acid: AmNA), replacement of 2'-NH2 and 4'-H with 2'-NH-C 1~6 Substitution to alkylene-4' (e.g., 2'-NH-methylene-4'), 2'-H and 4'-H of 2'-C 1~6 Examples of 3'-5'-bridged modifications include 3'-C of 3'-H and 5'-H. 1~6 Substitution with alkylene-5' (eg, 3'-ethylene-5' (bicyclonucleic acid: Bc nucleic acid), a type of Bc nucleic acid: tc nucleic acid, etc.)) can be mentioned.

[0022] The carrier in the carrier addition modification may be a carrier for improving or imparting performance such as stability, targeting, or efficacy to the desired modified oligonucleotide. Such a carrier can be appropriately selected from known carriers depending on the intended use. Examples of the carrier include N-acetylgalactosamine (GalNAc), peptide, phosphate, cholesterol, tocopherol, aliphatic chain, and folic acid. The addition site in the carrier addition modification is preferably the 3' or 5' site corresponding to the end of the desired modified oligonucleotide.

[0023] Modified nucleotide residues (sugar backbone-substituted nucleotide residues) involving "substitution of the sugar moiety itself of the nucleotide residue" include, for example, nucleotide residues involving substitution of a 5-membered sugar with a 6-membered pseudosugar in oligonucleotides such as hexitol nucleic acid (HNA) and cyclohexenyl nucleic acid (CeNA). Further, modified nucleotide residues involving "substitution of the sugar moiety itself of the nucleotide residue" also include morpholino nucleic acid (PMO) residues, which are nucleotide analogue artificial compounds having a morpholino ring structure that are not decomposed by enzymes in vivo (e.g., nucleases such as RNase) and do not induce immune responses.

[0024] "Modification of the nucleobase moiety of a nucleotide residue" includes, for example, alkyl substitution of the nucleobase moiety of the nucleotide residue (eg, substitution of a methyl group at the 5-position of a cytosyl group).

[0025] "An oligonucleotide containing a complementary portion" refers to an oligonucleotide containing a structure in which complementary nucleotide sequences are paired together. Examples of "an oligonucleotide containing a complementary portion" include double-stranded oligonucleotides and single-stranded oligonucleotides containing a double-stranded structure (e.g., loop-type oligonucleotides such as hairpin-type oligonucleotides and dumbbell-type oligonucleotides). The double-stranded oligonucleotide may be a double-stranded oligonucleotide in which each strand is an oligonucleotide as described above, and examples thereof include double-stranded oligonucleotides such as double-stranded oligonucleotides RNA, double-stranded oligonucleotides DNA, heteroduplex oligonucleotides consisting of oligonucleotides RNA and oligonucleotides DNA, double-stranded oligonucleotides consisting of oligonucleotides RNA and RNA-DNA hybrid oligonucleotides, double-stranded oligonucleotides consisting of oligonucleotides DNA and RNA-DNA hybrid oligonucleotides, and double-stranded oligonucleotides consisting of RNA-DNA hybrid oligonucleotides. Examples of double-stranded oligonucleotides include siRNA and heteroduplex oligonucleotides. In an oligonucleotide containing a complementary portion, the portion in which complementary nucleotide sequences are paired together is called a "complementary portion". The term "complementary portion" refers not only to the complementary portion in an oligonucleotide containing a complementary portion, but also to the portion in an oligonucleotide starting fragment corresponding to the complementary portion in an oligonucleotide containing a complementary portion when an oligonucleotide containing a complementary portion is divided into oligonucleotide starting fragments. For convenience, any one of the complementary nucleotide sequences in the complementary portion may be called the "sense strand", and the other complementary nucleotide sequence may be called the "antisense strand". In the present invention, the terms "sense" and "antisense" are merely convenient names referring to any one and the other of the complementary portion, and are not intended to have a biological meaning (particularly, meaning in RNAi). An oligonucleotide containing a complementary portion may or may not contain a loop portion. The "loop portion" refers to a linker that connects the sense side and the antisense side of the complementary portion at the same end (e.g., the 5' end and the 3' end). An oligonucleotide containing a complementary portion is particularly used for post-transcriptional gene silencing (e.g., RNA interference (RNAi)).

[0026] The modified oligonucleotide of interest contains the above-mentioned modified residue in the complementary portion. The modified oligonucleotide of interest includes, for example, a double-stranded oligonucleotide or a loop-type oligonucleotide containing a modified nucleotide residue (e.g., a double-stranded oligonucleotide or a loop-type oligonucleotide containing a modified nucleotide residue in the complementary portion), and a loop-type oligonucleotide containing a modified nucleotide residue or a residue other than a nucleotide residue (e.g., an amino acid residue, a linker, etc.) in the loop portion (e.g., International Publication No. 2012 / 005368). In the modified oligonucleotide of interest, some nucleotide residues may be modified nucleotide residues, or all nucleotide residues may be modified nucleotide residues, but when the "modified nucleotide residue" is a morpholino nucleic acid (PMO) residue, it is preferable that some nucleotide residues in the modified oligonucleotide of interest are morpholino nucleic acid (PMO) residues. In addition, the modified oligonucleotide of interest includes gapmers, which are oligonucleotides having modified nucleotide residues at both ends of their sequence and a gap region in the center of their sequence that is recognized by RNase, and further includes oligonucleotides that do not induce RNase activity, such as mixmers, which are oligonucleotides whose sequence contains a mixture of modified nucleotide residues, and fully modified oligonucleotides, which are oligonucleotides in which all nucleotide residues in the sequence are modified nucleotide residues.

[0027] In the present invention, the complementary portion in the modified oligonucleotide of interest is 11 to 27 bases long (e.g., 12 to 27 bases long, 15 to 27 bases long, or 18 to 27 bases long). For example, when the modified oligonucleotide of interest is a double-stranded modified oligonucleotide consisting of only a complementary portion, it may be 11 to 27 bases long. Alternatively, the modified oligonucleotide of interest may have a non-complementary portion in addition to the complementary portion. In this case, the non-complementary portion may be 1 to 16 bases long, for example, 1 to 10 bases long, preferably 1 to 5 bases long, and more preferably 1, 2, or 3 bases long. In the modified oligonucleotide of interest having a non-complementary portion in addition to a complementary portion of 11 to 27 bases long, the complementary portion of 11 to 27 bases long may be in a continuous form, or may be in a non-contiguous form interrupted by a mismatch base pair as the non-complementary portion.

[0028] The total number of residues of the modified oligonucleotide of interest may be appropriately selected based on the function of the modified oligonucleotide of interest and each condition of the method of the present invention. The total number of residues of the modified oligonucleotide of interest may be, for example, 24 to 74.

[0029] (Oligonucleotide raw material fragment) The total of four or more oligonucleotide starting fragments used as starting materials in the method of the present invention can be designed to correspond to the oligonucleotide starting fragments obtained when a modified oligonucleotide of interest is divided at a fragment junction (also called a "cleavage site") that satisfies the following conditions (i) to (v): (i) there is at least one fragment linker on each strand of the complementary portion, and there are a total of two or more fragment linkers in the modified oligonucleotide; (ii) when the modified oligonucleotide is split at the fragment junction, a protruding end (also called a "sticky end") is formed in the complementary portion, and the protruding end is 1 to 10 bases long; (iii) at least one oligonucleotide starting fragment contains a modified nucleotide; (iv) four of the four or more oligonucleotide raw material fragments contain a complementary portion having a length of 5 to 25 bases; and (v) The total length of bases corresponding to each strand of the complementary portion of the oligonucleotide starting fragment is 11 to 27 bases.

[0030] The number of oligonucleotide raw material fragments is 4 or more, preferably 4 to 6 (4, 5, 6). The number of oligonucleotide raw material fragments can also be characterized from the viewpoint of the number mainly corresponding to the sense strand and the antisense strand constituting the desired modified oligonucleotide (mainly double-stranded nucleic acid). From the above condition (i), it is understood that the number of oligonucleotide raw material fragments mainly corresponding to such sense strands and antisense strands is 2 or more. The number of oligonucleotide raw material fragments corresponding to such sense strands and antisense strands may be 3 or 4 fragments, respectively, and preferably 2 or 3 fragments. The overhanging end in the above condition (ii) may be either a 5' overhanging end or a 3' overhanging end. The "complementary portion" in the above condition (iv) refers to a portion in the oligonucleotide raw material fragment that corresponds to the complementary portion in the desired modified oligonucleotide. In the present invention, the terms "fragment linking portion" and "cleavage site" have the same meaning. The "fragment linking portion" ("cleavage site") means a site that is conveniently set to design a combination of oligonucleotide raw material fragments, and does not mean a site that is actually cleaved in the method of the present invention. The four oligonucleotide starting fragments in (iv) above may be designed so that the desired modified oligonucleotide contains a complementary portion preferably 5 to 25 bases in length, more preferably 5 to 20 bases in length, and even more preferably 5 to 17 bases in length.

[0031] The base length of the "complementary portion" in the above condition (iv) may be one or more bases long as long as it can form a pair. In addition, since the purity, yield, and production efficiency of the product may decrease as the base length increases in oligonucleotide synthesis, it is preferable that four of the total oligonucleotide raw material fragments are designed so that the complementary portion is 17 bases or less in length. The two strands constituting the complementary portion are preferably 5 to 25 bases long (e.g., 5 to 22 bases long, 5 to 20 bases long, 5 to 17 bases long, 8 to 25 bases long, 8 to 22 bases long, 8 to 20 bases long, 8 to 17 bases long).

[0032] The protruding end is, for example, 1 to 10 bases long, preferably 1 to 8 bases long, more preferably 1 to 6 bases long, and even more preferably 2 to 6 bases long, 3 to 6 bases long, or 4 to 6 bases long.

[0033] The numerical value of the base length of the "complementary portion" in the above condition (iv) and the numerical value of the base length of the protruding end are set to values ​​that satisfy the above-mentioned range and match each other. For example, when the protruding end is 5 bases long, the complementary portion may be 6 to 25 bases long to form a protruding end, and when the protruding end is 6 bases long, the complementary portion may be 7 to 25 bases long to form a protruding end.

[0034] The portions other than the protruding ends in the "complementary portions" of the four oligonucleotide starting fragments defined by the above condition (iv) are preferably 4 to 24 bases long, 4 to 21 bases long, 4 to 19 bases long, or 4 to 16 bases long.

[0035] In a particular embodiment, the four oligonucleotide raw material fragments defined by the above condition (iv) may each be 5 bases or more, preferably 6 bases or more, more preferably 7 bases or more, even more preferably 8 bases or more, and particularly preferably 9 bases or more. Such four oligonucleotide raw material fragments may also be 19 bases or less, preferably 18 bases or less, more preferably 17 bases or less, even more preferably 16 bases or less, and particularly preferably 15 bases or less. Such four oligonucleotide raw material fragments may also be 5 to 19 bases, preferably 6 to 18 bases, more preferably 7 to 17 bases, even more preferably 8 to 16 bases, and particularly preferably 9 to 15 bases.

[0036] The 5'-end of the oligonucleotide starting fragment corresponding to the 5'-end of the desired modified oligonucleotide may remain as a 5'-phosphate group, may be substituted with 5'-OH, may have a 5'-phosphate group modification introduced, or may have the same structure as the 5'-end of the desired modified oligonucleotide. Examples of 5'-phosphate group modifications include those mentioned above. From the viewpoint of the ligation reaction by oligonucleotide ligase, it is preferable that the 5'-end of the other oligonucleotide starting fragments remain as a 5'-phosphate group. The 3'-end of the oligonucleotide starting fragment corresponding to the 3'-end of the desired modified oligonucleotide may remain as a 3'-OH, may have a 3'-phosphate group modification introduced, or may have the same structure as the 3'-end of the desired modified oligonucleotide. Examples of 3'-phosphate group modifications include those mentioned above. From the viewpoint of the ligation reaction by oligonucleotide ligase, it is preferable that the 3'-end of the other oligonucleotide starting fragments remain as a 3'-OH.

[0037] The oligonucleotide starting fragments may be in the free form, complexed, or immobilized.

[0038] The oligonucleotide starting fragment may be produced by known chemical synthesis or enzymatic synthesis, such as solid-phase synthesis or liquid-phase synthesis, for example, the methods described in WO 2012 / 157723 and WO 2005 / 070859.

[0039] If it is desired to add a functional moiety to the desired modified oligonucleotide, the oligonucleotide starting fragment may have the functional moiety added at the corresponding portion thereof.

[0040] (Ligase treatment) Oligonucleotide ligase is an enzyme that links oligonucleotide raw material fragments together. In the method of the present invention, oligonucleotide raw material fragments are linked together at the "cleavage site" (also called "linking site") by the catalytic action of oligonucleotide ligase to generate the desired modified oligonucleotide. Examples of oligonucleotide ligase include RNA ligase and DNA ligase. RNA ligase may be either single-stranded RNA ligase or double-stranded RNA ligase, and double-stranded RNA ligase is preferred. Examples of double-stranded RNA ligase include RNA ligase of the Rnl2 family (sometimes called "RNA ligase 2") and RNA ligase of the Rnl5 family. As the RNA ligase, any RNA ligase derived from any organism or virus species may be used as long as the object of the present invention is achieved, and for example, T4 phage-derived RNA ligase (T4RNA ligase 1, T4RNA ligase 2) may be used. As the DNA ligase, any DNA ligase derived from any organism or virus species may be used as long as it achieves the object of the present invention. For example, T4 phage-derived DNA ligase may be used.

[0041] The treatment in the presence of oligonucleotide ligase (hereinafter referred to as "ligase treatment") is a reaction in which oligonucleotide raw fragments are ligated by the catalytic action of oligonucleotide ligase. The operation of the ligase treatment is to mix the oligonucleotide raw fragments with the oligonucleotide ligase. In the ligase treatment, all the oligonucleotide raw fragments may be mixed with the oligonucleotide ligase to carry out the ligation reaction in one step. In addition, in the ligase treatment, as a multi-step ligation reaction, after mixing some of the oligonucleotide raw fragments with the oligonucleotide ligase to carry out the ligation reaction, the remaining oligonucleotide raw fragments and the reactants may be mixed to carry out the next ligation reaction. The mixing may be adding the oligonucleotide ligase to the oligonucleotide raw fragments, adding the oligonucleotide raw fragments to a system containing the oligonucleotide ligase, or adding the oligonucleotide raw fragments and the oligonucleotide ligase to a system for the reaction.

[0042] An aqueous solution can be used as the system for carrying out the ligase treatment. As the aqueous solution, a buffer solution is preferable. Examples of the buffer solution include phosphate buffer, Tris buffer, carbonate buffer, acetate buffer, and citrate buffer. The pH may be, for example, about 5 to 9. For example, when the concentration of the oligonucleotide raw material fragment in the ligase treatment is high, the pH may be 7.5 to 9.0 (for example, 8.0 to 8.5).

[0043] The concentration of each oligonucleotide raw material fragment in the ligase treatment may be sufficient so long as the oligonucleotide raw material fragment dissolves and produces the desired modified oligonucleotide. The concentration of each oligonucleotide raw material fragment may be, for example, 1 μM or more, 10 μM or more, 50 μM or more, 100 μM or more, 300 μM or more, 500 μM or more, or 1000 μM or more. The concentration of each oligonucleotide raw material fragment may also be, for example, 1 M, 100 mM, or 10 mM or less. When efficient mass production of the desired modified oligonucleotide is particularly desired, it is preferable to use each oligonucleotide raw material fragment at a concentration of 100 μM or more among the above concentrations and in a pH range of 7.5 to 9.0 among the above pH ranges.

[0044] The molar number of all oligonucleotide raw material fragments in the ligase treatment is preferably approximately equal in terms of improving production efficiency by reducing the amount of unreacted oligonucleotide raw material fragments. In order to make the molar number of all oligonucleotide raw material fragments approximately equal, the total molar ratio of any two oligonucleotide raw material fragments selected from a total of four or more oligonucleotide raw material fragments may be within the range of, for example, 0.5 to 2, preferably 1 / 1.8 to 1.8, more preferably 1 / 1.5 to 1.5, even more preferably 1 / 1.2 to 1.2, and particularly preferably 1 / 1.1 to 1.1.

[0045] The concentration of the oligonucleotide ligase in the ligase treatment may be sufficient to generate the desired modified oligonucleotide. The concentration of the oligonucleotide ligase may be, for example, 0.01 U / μL or more, preferably 0.02 U / μL or more, more preferably 0.03 U / μL or more, and even more preferably 0.04 U / μL or more. The concentration of the oligonucleotide ligase may be, for example, 1 U / μL or less, preferably 0.5 U / μL or less, more preferably 0.2 U / μL or less, and even more preferably 0.1 U / μL or less. More specifically, the concentration of the oligonucleotide ligase may be, for example, 0.01 to 1 U / μL, preferably 0.02 to 0.5 U / μL, more preferably 0.03 to 0.2 U / μL, and even more preferably 0.04 to 0.1 U / μL.

[0046] The ligase treatment system may contain a cofactor for oligonucleotide ligase. Examples of the cofactor for oligonucleotide ligase include ATP and divalent metal salts (e.g., magnesium salts such as magnesium chloride). The treatment system may contain a stabilizer for oligonucleotide ligase. Examples of the stabilizer for oligonucleotide ligase include antioxidants (e.g., reducing agents such as dithiothreitol and mercaptoethanol). The ligase treatment system may contain a surfactant to stably maintain the enzyme and improve the reaction rate. Examples of the surfactant include nonionic surfactants (e.g., Triton series surfactants such as Triton X-100) and ionic surfactants. Examples of the ionic surfactant include cationic surfactants, anionic surfactants, and amphoteric surfactants. The ligase treatment system may also contain polyethylene glycol to improve the reaction rate.

[0047] The system in which the ligase treatment is carried out may have a low monovalent cation salt concentration or may be substantially free of monovalent cation salts. The monovalent cation salt concentration in the treatment system may be, for example, 10 mM or less, preferably 1 mM or less, more preferably 0.1 mM or less, and even more preferably 0.01 mM or less. Particularly preferably, the treatment system may be substantially free of monovalent cation salts. Examples of monovalent cation salts include salts of monovalent cations such as lithium ions, sodium ions, potassium ions, rubidium ions, cesium ions, and ammonium ions, and anions such as fluoride ions, chloride ions, bromide ions, and iodide ions.

[0048] The temperature in the ligase treatment may be any temperature sufficient to activate the oligonucleotide ligase, for example, 2 to 50°C, preferably 16 to 50°C, and more preferably 25 to 50°C.

[0049] The time for which the ligase treatment is carried out may be any time sufficient to produce the desired modified oligonucleotide, and may be, for example, 1 to 72 hours.

[0050] According to the present invention, it is possible to suppress the generation and incorporation of impurities having a base length other than the desired base length, such as N-1mer or N+1mer, in the modified oligonucleotide of interest. For example, in the present invention, the modified oligonucleotide of interest is produced as a single double-stranded nucleic acid (e.g., siRNA, heteroduplex oligonucleotide). The sense strand and the antisense strand constituting such a single double-stranded nucleic acid are N and M bases long, respectively. The base lengths of N and M are each independently 11 to 30 bases long (e.g., 18 to 30 bases long). The base lengths of N and M may also each independently be 11 to 27 bases long (e.g., 18 to 27 bases long). In the present invention, the impurities of the modified oligonucleotide of interest are intended to be nucleic acid contaminants other than the modified oligonucleotide of interest. The sense and antisense strands constituting such nucleic acid contaminants are not N and M bases long, but (N±α) and M bases long, N and (M±β) bases long, or (N±α) and (M±β) bases long, where N and M are the same as above, and α and β are, for example, 1, 2, or 3.

[0051] (Other optional steps) The method of the present invention may include a step of synthesizing an oligonucleotide raw material fragment (e.g., chemical synthesis such as solid-phase synthesis). Since the method of the present invention can suppress the generation of nucleic acid contaminants other than the desired modified oligonucleotide, purification of the desired modified oligonucleotide from a sample of the synthesized oligonucleotide raw material fragment can be omitted. However, even if the desired modified oligonucleotide is purified, the method of the present invention can suppress the generation of double-stranded nucleic acid contaminants (impurities) due to a small amount of undesired oligonucleotide raw material fragments that may remain after the purification, so the desired modified oligonucleotide may be purified. Such purification can be performed, for example, by methods such as chromatography (e.g., HPLC, IEX), gel filtration, etc.

[0052] The method of the present invention may include a reaction termination step after the ligase treatment step. Examples of the reaction termination step include high temperature treatment (e.g., 80°C), inactivation of oligonucleotide ligase by addition of acid, alkali, or organic solvent, and removal of metal ions of cofactors by addition of a chelating agent such as EDTA. Another example is a method in which the enzyme is immobilized on a carrier to carry out the reaction, and then the enzyme is removed from the reaction solution by membrane separation.

[0053] The method of the invention may also include a step of purifying the desired modified oligonucleotide after the ligation step, for example by any suitable method, such as chromatography (e.g., HPLC), gel filtration, etc.

[0054] In the case of annealing oligonucleotide raw fragments, generally, in order to make the oligonucleotide raw fragments in a denatured state (non-paired state), the oligonucleotide raw fragment mixed solution is heated to a high temperature, and then, in order to form pairing between complementary nucleotide sequences, the high-temperature oligonucleotide raw fragment mixed solution is gradually cooled by air cooling or the like. However, in the method of the present invention, the desired modified oligonucleotide can be produced by a simplified operation without performing such a heating operation for denaturation and a cooling treatment for pairing (heating-cooling treatment) before the ligase treatment step. Examples of placing at a high temperature include holding the oligonucleotide raw fragment mixed solution at 65°C or higher, 70°C or higher, 75°C or higher, 80°C or higher, 85°C or higher, 90°C or higher, 95°C or higher, or 100°C or higher (e.g., 5 minutes or more, or 10 minutes or more). Examples of cooling include leaving the oligonucleotide raw material fragment mixed solution at room temperature (e.g., 15 to 25°C, or 20 to 25°C) or a predetermined temperature (e.g., 37°C) (e.g., for 5 hours or more), and maintaining the oligonucleotide raw material fragment mixed solution at a predetermined temperature (e.g., 37°C) (e.g., for 15 minutes or more).

[0055] In order to omit the heating-cooling process, the time for which the oligonucleotide raw fragment mixed solution is exposed to high temperatures before the ligase treatment step may be controlled to be, for example, less than 5 minutes, 4.5 minutes or less, 4 minutes or less, 3.5 minutes or less, 3 minutes or less, 2.5 minutes or less, 2 minutes or less, 1.5 minutes or less, 1 minute or less, or 0.5 minutes or less.

[0056] To omit the heating-cooling treatment, in the method of the present invention, the solution containing the oligonucleotide raw material fragments may be kept at 2 to 50°C from the time when the oligonucleotide raw material fragments are mixed in the solution until the ligase treatment step is carried out. That is, in the method of the present invention, any mixing of all the oligonucleotide raw material fragments and oligonucleotide ligase contained in the above combination and any intervals between mixings, as well as the ligase reaction, may be carried out under conditions of 2 to 50°C. In such an embodiment, the method of the present invention includes the following: (1) mixing all of the oligonucleotide raw material fragments and oligonucleotide ligase contained in the above combination, which are present in separate systems, under conditions in which all mixing is performed at 2 to 50°C and the mixture is maintained at 2 to 50°C during all intervals between mixings to obtain a mixed solution; and (2) Reacting the mixed solution while keeping it at 2 to 50°C to obtain a solution containing the desired modified oligonucleotide.

[0057] In this embodiment, all of the oligonucleotide raw material fragments contained in the above combination are obtained in separate systems. In this embodiment, the present invention may be carried out, for example, by mixing the oligonucleotide raw material fragments at 2 to 50°C to obtain an oligonucleotide raw material fragment mixture, and mixing the oligonucleotide raw material fragment mixture with oligonucleotide ligase at 2 to 50°C. In this embodiment, the present invention may be carried out, for example, by sequentially adding the oligonucleotide raw material fragments to a solution containing oligonucleotide ligase at 2 to 50°C.

[0058] The methods of the present invention can be used, for example, for the industrial production of modified oligonucleotides of interest on a large scale. EXAMPLES

[0059] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to the following examples.

[0060] [Example 1] Comparison of fragment combination patterns using natural RNA 1) Synthesis of substrate and product preparations The effect of the base length of the fragments was evaluated in the reaction of enzymatically synthesizing siRNA from four short natural RNA fragments. The target siRNA was a double strand consisting of RNA1-S (21mer) and RNA1-A (23mer) in Table 1 (hereinafter referred to as the sense strand and antisense strand, respectively). The 18 types of RNA fragments shown in Table 1 were synthesized, and the six patterns of fragment combinations shown in Table 2 were evaluated using these.

[0061] [Table 1]

[0062] [Table 2]

[0063] 2) Ligation reaction using T4 RNA ligase 2 The four oligonucleotide fragments were reacted with T4 RNA ligase 2 (New England Biolabs). The reaction solution consisted of 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5, and 10 μM of RNA fragments, and the reaction solution volume was 10 μL. The enzyme was added at concentrations of 0.025, 0.05, 0.1, and 0.2 U / μL to compare the product concentrations. After reacting at 25°C for 1 hour using a thermal cycler, the reaction was stopped by heating at 80°C for 5 minutes.

[0064] 3) Analysis by HPLC The reaction solution was analyzed by HPLC using an Xbridge Oligonucleotide BEH C18 column (Waters, 2.5 μm, 4.6 mm × 50 mm). The analysis conditions were: column temperature 60°C, detection wavelength 254 nm, injection volume 10 μL, and flow rate 0.4 mL / min. The mobile phase was a linear gradient using eluent A (hexafluoroisopropanol-triethylamine) and eluent B (methanol). The concentrations of the ligation products were quantified by analyzing the sense and antisense strand preparations in the same manner.

[0065] 4) Results The accumulation of the sense and antisense strands for each combination of fragment base lengths is shown in Figure 2. Although almost no ligation product accumulated in combination 3, it was observed that the accumulation of the ligation product increased with increasing enzyme concentration in the other combinations.

[0066] [Example 2] Evaluation of the effect of reaction temperature on the ligation reaction of natural RNA The effect of reaction temperature on the ligation reaction of short chains was examined. The oligonucleotide 1 in Table 2 was used as a substrate, and the reaction was performed with T4 RNA ligase 2. The composition of the reaction solution was 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5, enzyme concentration 0.2 U / μL, and RNA fragments were each 10 μM, and the reaction solution volume was 10 μL. The reaction temperatures were 16°C, 25°C, 30°C, and 37°C, and the reaction was stopped after 1, 2, and 4 hours of reaction, respectively, by heating at 80°C for 5 minutes. The concentration of the ligation product contained in the reaction solution was analyzed by HPLC under the conditions described in Example 1.

[0067] The results are shown in Figure 3. At reaction temperatures of 25°C or higher, approximately 10 μM of ligation products accumulated for both the sense and antisense strands after 1 hour of reaction. On the other hand, the rate of production of ligation products, especially of the sense strand, was slower at 16°C than at temperatures above 25°C.

[0068] [Example 3] Confirmation of reaction progress using modified RNA 1) Synthesis of substrate and product preparations The progress of the enzymatic ligation reaction of siRNA from the four fragments in the modified oligonucleotide was evaluated. The target siRNA was a double strand consisting of a sense strand (MOD1-S) and an antisense strand (MOD1-A) shown in Table 3. This siRNA has the same base sequence as the natural RNA used in Examples 1 and 2, but all residues are modified with 2'-F or 2'-O-methyl, and some phosphate groups are replaced with thiophosphate groups. In addition, the four fragments shown in Table 3 were synthesized as each fragment. The base sequences of these four fragments are the same as the combination of number 1 in Table 2.

[0069] [Table 3]

[0070] 2) Ligation reaction using T4 RNA ligase 2 The reaction was carried out using T4 RNA ligase 2 with four modified RNA fragments. The reaction solution consisted of 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5, and 10 μM of each modified RNA fragment. The reaction volume was 50 μL. The enzyme was added at a concentration of 0.2 or 1.0 U / μL, and the reaction was also carried out without enzyme addition as a negative control. After the reaction was carried out at 25°C for 1 hour using a thermal cycler, the reaction was stopped by heating at 80°C for 5 minutes.

[0071] 3) Analysis by HPLC and LC-TOF / MS The reaction solution was analyzed by HPLC using an ACQUITY UPLC Oligonucleotide BEH C18 Column (Waters, 2.1 × 100 mm, 1.7 μm). The analysis conditions were: column temperature 80 °C, detection wavelength 260 nm, injection volume 10 μL, and flow rate 0.4 mL / min. The mobile phase was a linear gradient using solution A (hexafluoroisopropanol-triethylamine) and solution B (methanol). The generation of ligation products was confirmed by analyzing the sense and antisense strand preparations in the same manner. In addition, mass spectrometry of the ligation products was performed using an Agilent 6230 TOF LC / MS system (Agilent technologies).

[0072] 4) Results The results of the HPLC analysis are shown in Figure 4. In the HPLC analysis, the addition of the enzyme resulted in a peak of the ligation product at the retention time consistent with that of the standard, and the peak area of ​​the modified RNA substrate decreased compared to the negative control. The peak area of ​​the ligation product also increased with increasing amounts of enzyme added. Furthermore, in the LC-TOF / MS analysis of the reaction solution, the production of both sense and antisense strands was observed under the enzyme addition conditions. Sense strand LC / MS m / z: calcd 2266.13, found 2265.9703[M-3H] 3- Antisense strand LC / MS m / z: calcd 2531.04, found 2531.0199[M-3H] 3-

[0073] These results demonstrate that T4 RNA ligase 2 can generate siRNA from four fragments of modified RNA.

[0074] [Example 4] Confirmation of reaction progress using DNA ligase The progress of the enzymatic ligation reaction of siRNA from the four fragments in the modified oligonucleotide was evaluated using DNA ligase, T4 DNA ligase (New England Biolabs).

[0075] The composition of the reaction solution was DNA ligase, 50 mM Tris-HCl, 10 mM MgCl2, 10 mM dithiothreitol, 1 mM ATP, pH 7.5. The enzyme concentration was 470 nM, the oligonucleotide fragments were each 10 μM, and the reaction solution volume was 30 μL. The oligonucleotide fragments were used in the combination shown in Table 3. The reaction was carried out at 25°C using a thermal cycler, and 10 μL was taken after 4 hours and heated at 80°C for 5 minutes to stop the reaction. The concentration of the ligation product contained in the reaction solution was analyzed by HPLC under the conditions described in Example 3. The concentration of the ligation product was quantified by analyzing the standard sample in the same manner.

[0076] Analysis by HPLC confirmed the accumulation of ligation products, with the sense strand and antisense strand accumulated at 0.58 μM and 5.1 μM, respectively, after 4 hours of reaction. As described above, the reaction to generate siRNA from the four modified RNA fragments also proceeded using DNA ligase.

[0077] Example 5: Preparation of Deinococcus radiodurans RNA ligase and ligation reaction (1) Construction of recombinant expression strain in E. coli A strain expressing DraRnl, an RNA ligase belonging to the Rnl5 family derived from Deinococcus radiodurans, in E. coli was constructed, and a purified enzyme was prepared. First, a plasmid carrying the amino acid sequence of DraRnl (SEQ ID NO: 17) optimized for E. coli codons was created by total gene synthesis, and this sequence was then subcloned into the NdeI / BamHI site of the pET16b vector. This expression plasmid was transformed into E. coli BL21(DE3) to obtain a DraRnl expression strain. This expression strain expresses DraRnl with a His-tag at the N-terminus.

[0078] (2) Preparation of recombinant enzyme Each expression strain was grown overnight at 37°C on LB agar medium containing 100 mg / L ampicillin. The resulting colonies were inoculated into 100 mL of LB medium containing 100 mg / L ampicillin, and cultured with shaking using a Sakaguchi flask. After culturing for 2 hours at 37°C, IPTG and ethanol were added to a final concentration of 0.1 mM and 2%, respectively. The strain was further cultured at 17°C for 16 hours.

[0079] After the cultivation, the cells were collected from the culture by centrifugation, suspended in a buffer solution consisting of 50 mM Tris-HCl (pH 7.6), 250 mM NaCl, 10% sucrose, 15 mM imidazole, 1% lysozyme, and 0.1% Triton-X100, and disrupted by ultrasonication. The cell debris was removed from the disrupted solution by centrifugation, and the resulting supernatant was used as the soluble fraction.

[0080] The obtained soluble fraction was applied to a His-tag protein purification column HisTALON Superflow Cartridge (Takara Bio) equilibrated with the above buffer, and was adsorbed onto the carrier. Proteins that were not adsorbed onto the carrier (non-adsorbed proteins) were washed away with a buffer consisting of 50 mM Tris-HCl (pH 7.6), 250 mM NaCl, 10% sucrose, and 15 mM imidazole, and then the adsorbed proteins were eluted with a buffer consisting of 50 mM Tris-HCl (pH 8.0), 250 mM NaCl, 10% glycerol, and 200 mM imidazole.

[0081] The eluted fractions containing the enzyme were collected and buffer exchanged into a buffer consisting of 50 mM Tris-HCl (pH 8.0), 200 mM NaCl, 2 mM DTT, 2 mM EDTA, 10% glycerol, and 0.1% Triton X-10 using an Amicon Ultra-15 10 kDa (Merck Millipore) to obtain a purified enzyme solution.

[0082] (3) Ligation reaction with DraRnl The reaction was carried out with DraRnl using four modified RNA fragments. The reaction solution consisted of 50 mM Tris-HCl (pH 7.5), 10 mM MnSO4, 1 mM dithiothreitol, 400 μM ATP, and 10 μM of each modified RNA fragment, with a reaction volume of 25 μL. The modified RNA fragments used were in the combinations shown in Table 3. The enzyme was added at a concentration of 72 μg / mL, and the reaction was also carried out without enzyme addition as a negative control. After 3 hours of reaction at 25°C using a thermal cycler, the reaction was stopped by adding EDTA to a final concentration of 1 mM.

[0083] (4) Analysis by HPLC The reaction solution was analyzed by HPLC using an ACQUITY HPLC Oligonucleotide BEH C18 Column (Waters, 2.1 x 100 mm, 1.7 μm). The analysis conditions were: column temperature 60°C, detection wavelength 260 nm, injection volume 10 μL, and flow rate 0.4 mL / min. The mobile phase was a linear gradient using solution A (hexafluoroisopropanol-triethylamine) and solution B (methanol). The generation of ligation products was confirmed by analyzing the sense and antisense strand samples in the same manner.

[0084] The results of the HPLC analysis are shown in Figure 5. In the HPLC analysis, the addition of the enzyme resulted in a peak of the ligation product at the same retention time as the standard, and the peak area of ​​the modified RNA substrate was reduced compared to the negative control. These results demonstrate that DraRnl can produce the desired modified oligonucleotide from the four fragments of modified RNA.

[0085] [Example 6] Preparation of modified oligonucleotides having a loop structure The progress of the reaction to generate a modified oligonucleotide with a loop structure by enzymatic ligation from four oligonucleotide fragments was evaluated. The sequences of the target product and the synthesized substrate fragments are shown in Table 4.

[0086] [Table 4]

[0087] The reaction was carried out using T4 RNA ligase 2 (New England Biolabs) with the substrate oligonucleotides of the four fragments in Table 4. The composition of the reaction solution was 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5, and 10 μM of each oligonucleotide fragment, and the reaction solution volume was 100 μL. The concentration of the enzyme added was 17.8 μg / μL, and the product concentration was compared. As a negative control, the reaction was also carried out under conditions without adding enzyme. After reacting for 3 hours at 25°C using a thermal cycler, the reaction was stopped by heating at 80°C for 5 minutes. The reaction solution was analyzed by HPLC and LC-TOF / MS under the conditions of Example 5.

[0088] In the HPLC analysis, the addition of the enzyme reduced the peak area of ​​the modified RNA substrate compared to the negative control, and a peak was detected at a position with a longer retention time (around 5.6 minutes) compared to the substrate, as shown in Figure 6. Furthermore, in the LC-TOF / MS analysis of the reaction solution, the target product was observed under the enzyme addition condition. LC / MS m / z: calcd 2727.33, found 2727.21[M-6H] 6-

[0089] These results demonstrate that T4 RNA ligase 2 can be used to generate the desired modified oligonucleotide with a loop structure from four fragments.

[0090] [Example 7] Formation of heteroduplex consisting of DNA strand and RNA strand A heteroduplex consisting of a modified DNA strand and a modified RNA strand was generated using double-stranded RNA ligase, T4 RNA ligase 2 (New England Biolabs).

[0091] The composition of the reaction solution was 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5. The enzyme concentration was 3.56 μg / mL, the substrate was 10 μM of each of the four oligonucleotide fragments shown in Table 5, and the reaction solution volume was 40 μL. The reaction was carried out at 37°C using a thermal cycler, and the reaction was stopped after 18 hours by adding EDTA to a final concentration of 10 mM. As a negative control, the reaction was also carried out under conditions without the addition of enzyme. The concentration of the ligation product contained in the reaction solution was analyzed by HPLC and LC-TOF / MS under the conditions described in Example 5.

[0092] In HPLC analysis, the peak areas of each substrate were reduced by the addition of the enzyme compared to the negative control, and two new peaks were detected. Furthermore, in LC-TOF / MS analysis of the reaction mixture, the production of modified DNA strands and modified RNA strands was observed under the enzyme addition condition. Modified DNA strand LC / MS m / z: calcd 2119.50, found 2119.34[M-2H] 2- Modified RNA strand LC / MS m / z: calcd 2126.89, found 2126.36[M-2H] 2-

[0093] These results demonstrate that T4 RNA ligase 2 can generate heteroduplexes consisting of modified DNA and RNA strands.

[0094] [Table 5]

[0095] [Example 8] Reaction using oligonucleotide fragments containing mismatched base pairs The progress of the reaction to generate a double-stranded modified oligonucleotide with mismatched base pairs by enzymatic ligation from four oligonucleotide fragments was evaluated. The target product strands were designated as strand A and strand B. The sequences of the target product and the synthesized substrate fragments are shown in Table 6, and the combinations of the four fragments are shown in Figure 7.

[0096] The composition of the reaction solution was 1.78 μg / mL T4 RNA ligase 2 (New England Biolabs), 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5. Four oligonucleotide fragments were added as substrates to a final concentration of 10 μM, and the reaction was carried out in a volume of 40 μL. The reaction was carried out at 25°C using a thermal cycler, and the reaction was stopped after 4 hours by adding EDTA to a final concentration of 10 mM. As a negative control, the reaction was also carried out under conditions without the addition of enzyme. The concentration of the ligation product contained in the reaction solution was analyzed by HPLC and LC-TOF / MS under the conditions described in Example 5.

[0097] In HPLC analysis, the peak areas of each substrate were reduced by the addition of the enzyme compared to the negative control, and two new peaks were detected. Furthermore, LC-TOF / MS analysis of the reaction mixture confirmed the production of chains A and B under the enzyme addition conditions. A chain LC / MS m / z: calcd 1361.77, found 1361.75[M-5H] 5- B chain LC / MS m / z: calcd 1517.41, found 1517.35[M-5H] 5-

[0098] These results demonstrate that T4 RNA ligase 2 can generate double-stranded modified oligonucleotides having mismatch sequences.

[0099] [Table 6]

[0100] [Example 9] Reaction using oligonucleotides of fragments 5 and 6 The progress of the reaction to generate double-stranded modified oligonucleotides by enzymatic ligation from 5-fragment and 6-fragment oligonucleotides was evaluated. The respective strands of the target product were designated as strand A and strand B. The sequences of the target product and the synthesized substrate fragments are shown in Table 7, and the combination of the 4 fragments is shown in Figure 8.

[0101] The composition of the reaction solution was 1.78 μg / mL T4 RNA ligase 2 (New England Biolabs), 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5. As substrates, oligonucleotide fragments were added to a final concentration of 10 μM, and the reaction was carried out in a volume of 30 μL. The reaction was carried out at 37°C using a thermal cycler, and the reaction was stopped after 16 hours by adding EDTA to a final concentration of 10 mM. As a negative control, the reaction was also carried out under conditions without the addition of enzyme. The concentration of the ligation product contained in the reaction solution was analyzed by HPLC under the conditions described in Example 5.

[0102] In the HPLC analysis, the peak areas of each substrate were reduced by the addition of the enzyme compared to the negative control, and two new peaks were detected, as shown in Figure 9. The retention times of these peaks were consistent with those of the product standards.

[0103] These results demonstrate that T4 RNA ligase 2 can generate double-stranded modified oligonucleotides from 5- and 6-fragment substrate oligonucleotides.

[0104] [Table 7]

[0105] [Example 10] Reaction using an oligonucleotide having a DMTr group added to the 5' end The progress of the reaction to generate a double-stranded modified oligonucleotide by enzymatic ligation from four oligonucleotide fragments, including two fragments with a dimethoxytrityl (DMTr) group added to the 5' end, was evaluated. The respective strands of the target product were designated as strand A and strand B. The sequences of the target product and the synthesized substrate fragments are shown in Table 8, and the combinations of the four fragments are shown in Figure 10.

[0106] The composition of the reaction solution was 1.78 μg / mL T4 RNA ligase 2 (New England Biolabs), 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5. Four oligonucleotide fragments were added as substrates to a final concentration of 10 μM, and the reaction was carried out in a volume of 40 μL. The reaction was carried out at 25°C using a thermal cycler, and the reaction was stopped after 4 hours by adding EDTA to a final concentration of 10 mM. As a negative control, the reaction was also carried out under conditions without the addition of enzyme. The concentration of the ligation product contained in the reaction solution was analyzed by HPLC and LC-TOF / MS under the conditions described in Example 5.

[0107] In HPLC analysis, the peak areas of each substrate were reduced by the addition of the enzyme compared to the negative control, and two new peaks were detected. Furthermore, LC-TOF / MS analysis of the reaction mixture confirmed the production of chains A and B under the enzyme addition conditions. A chain LC / MS m / z: calcd 1764.80, found 1764.79[M-4H] 4- B chain LC / MS m / z: calcd 1738.76, found 1738.75[M-4H] 4-

[0108] These results demonstrate that T4 RNA ligase 2 can generate double-stranded modified oligonucleotides from substrate fragments bearing DMTr groups.

[0109] [Table 8]

[0110] [Example 11] Reaction using carrier-added oligonucleotide fragment The progress of the reaction to generate a double-stranded modified oligonucleotide by enzymatic ligation from four oligonucleotide fragments, including one fragment with N-acetylgalactosamine (GalNAc) added to the 5'-terminus, was evaluated. The target product strands were designated as strand A and strand B. The target product and the synthesized substrate fragment sequences are shown in Table 9, and the combinations of the four fragments are shown in Figure 11. The GalNAc-modified fragment was synthesized by linking Trivalent β-D-GalNAc with carboxyl-functionalized PEG5 Linker (Sussex) to the 5'-terminus of the oligonucleotide via an amino C6 linker.

[0111] The composition of the reaction solution was 1.78 μg / mL T4 RNA ligase 2 (New England Biolabs), 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5. Four oligonucleotide fragments were added as substrates to a final concentration of 10 μM, and the reaction was carried out in a volume of 40 μL. The reaction was carried out at 25° C. using a thermal cycler, and the reaction was stopped after 4 hours by adding EDTA to a final concentration of 10 mM. As a negative control, the reaction was also carried out under conditions without the addition of enzyme. The ligation products contained in the reaction solution were analyzed by HPLC and LC-TOF / MS under the conditions described in Example 5.

[0112] In HPLC analysis, the peak areas of each substrate were reduced by the addition of the enzyme compared to the negative control, and two new peaks were detected. Furthermore, in LC-TOF / MS analysis of the reaction mixture, A-chain and B-chain were detected under the enzyme addition condition, confirming their production. A chain LC / MS m / z: calcd 1730.40, found 1730.37[M-5H] 5- B chain LC / MS m / z: calcd 1330.38 found 1330.36[M-5H]5-

[0113] These results demonstrate that a double-stranded modified oligonucleotide with N-acetylgalactosamine at the termini can be produced by reacting four fragments with T4 RNA ligase 2.

[0114] [Table 9]

[0115] [Example 12] Reaction for producing a double-stranded modified oligonucleotide having a phosphorothiodiester bond at the linker The progress of the reaction to generate a double-stranded modified oligonucleotide by enzymatic ligation from four oligonucleotide fragments in which the phosphate group was replaced with a thiophosphate group was evaluated. The target product strands were designated as strand A and strand B. The sequences of the target product and the synthesized substrate fragments are shown in Table 10, and the combination of the four fragments is shown in Figure 12.

[0116] The composition of the reaction solution was 1.78 μg / mL T4 RNA ligase 2 (New England Biolabs), 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5. Four oligonucleotide fragments were added as substrates to a final concentration of 10 μM, and the reaction was carried out in a volume of 40 μL. The reaction was carried out at 25° C. using a thermal cycler, and the reaction was stopped after 4 hours by adding EDTA to a final concentration of 10 mM. As a negative control, the reaction was also carried out under conditions without the addition of enzyme. The ligation products contained in the reaction solution were analyzed by HPLC and LC-TOF / MS under the conditions described in Example 5.

[0117] In HPLC analysis, the peak areas of each substrate were reduced by the addition of the enzyme compared to the negative control, and two new peaks were detected. Furthermore, in LC-TOF / MS analysis of the reaction mixture, A-chain and B-chain were detected under the enzyme addition condition, confirming their production. A chain LC / MS m / z: calcd 1769.15, found 1769.13[M-4H] 4- B chain LC / MS m / z: calcd 1743.11 found 1743.10[M-4H] 4-

[0118] These results demonstrate that a double-stranded modified oligonucleotide having a phosphorothioate bond at the junction can be produced by reacting four fragments with T4 RNA ligase 2.

[0119] [Table 10]

[0120] [Example 13] Reaction for producing hairpin-type oligonucleotide The progress of the reaction to generate hairpin-type oligonucleotides by enzymatic ligation from four oligonucleotide fragments was evaluated. The sequences of the target product and the synthesized substrate fragments are shown in Table 11, and the combination of the four fragments is shown in Figure 13. The proline derivative described in the literature (Hamasaki T, Suzuki H, Shirohzu H, et al. Efficacy of a novel class of RNA interference therapeutic agents. PLoS ONE. 2012;7(8):e42655.) was used as the linker.

[0121] The composition of the reaction solution was 1.78 μg / mL T4 RNA ligase 2 (New England Biolabs), 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5. Four oligonucleotide fragments were added as substrates to a final concentration of 10 μM, and the reaction was carried out in a volume of 40 μL. The reaction was carried out at 25° C. using a thermal cycler, and the reaction was stopped after 4 hours by adding EDTA to a final concentration of 10 mM. As a negative control, the reaction was also carried out under conditions without the addition of enzyme. The ligation products contained in the reaction solution were analyzed by HPLC and LC-TOF / MS under the conditions described in Example 5.

[0122] In HPLC analysis, the peak areas of each substrate were reduced by the addition of the enzyme compared to the negative control, and one new peak was detected. Furthermore, in LC-TOF / MS analysis of the reaction solution, the target product was detected under the enzyme addition condition, confirming its production. LC / MS m / z: calcd 1891.61 found 1891.60[M-9H] 9-

[0123] These results demonstrate that hairpin oligonucleotides can be produced from four fragments by reaction with T4 RNA ligase 2.

[0124] [Table 11]

[0125] [Example 14] Effect of base length of overhanging end on reactivity The substrate oligonucleotides were designed to form the same product and overhanging ends of 1 to 6 bases in length, and the difference in reactivity due to the difference in base length of the overhanging end was compared. The target product strands were designated as A strand and B strand. In each combination, the substrate constituting B strand had a common sequence, and the cleavage position of A strand was set to a different position. The sequences of the synthesized target product specimens and substrate fragments are shown in Table 12, and the combinations of the four fragments are shown in Figure 14.

[0126] The composition of the reaction solution was 1.78 μg / mL T4 RNA ligase 2 (New England Biolabs), 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5. Four oligonucleotide fragments were added as substrates to a final concentration of 10 μM, and the reaction was carried out in a volume of 40 μL. The reaction was carried out at 25°C using a thermal cycler, and 5 μL was collected after 15 minutes, 30 minutes, 1 hour, 2 hours, and 4 hours, and the reaction was stopped by adding EDTA to a final concentration of 10 mM. As a negative control, the reaction was also carried out under conditions without the addition of enzyme. The concentrations of the ligation product and product preparation contained in the reaction solution were analyzed by HPLC under the conditions described in Example 5, and the concentration of the ligation product was calculated.

[0127] HPLC analysis confirmed that A- and B-strands were produced at protruding ends of all base lengths. The reaction rate tended to be slow with a protruding end of 1 base length.

[0128] [Table 12]

[0129] [Example 15] Effect of base length of product on reactivity The difference in reactivity was compared when short target products consisting of complementary portions of 11 to 14 bases in length were produced. The target product strands were designated as strand A and strand B. The sequences of the target products and the synthesized substrate fragments are shown in Table 13, and the combinations of the four fragments are shown in Figure 15.

[0130] The composition of the reaction solution was 1.78 μg / mL T4 RNA ligase 2 (New England Biolabs), 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5. Four oligonucleotide fragments were added as substrates to a final concentration of 10 μM, and the reaction was carried out in a volume of 40 μL. The reaction was carried out at 25° C. using a thermal cycler, and the reaction was stopped after 4 hours by adding EDTA to a final concentration of 10 mM. As a negative control, the reaction was also carried out under conditions without the addition of enzyme. The ligation products contained in the reaction solution were analyzed by HPLC and LC-TOF / MS under the conditions described in Example 5.

[0131] In HPLC analysis, the peak area of ​​each substrate was reduced by the addition of the enzyme compared to the negative control, and a new peak was detected at a later retention time. Furthermore, in LC-TOF / MS analysis of the reaction solution, as shown in Table 14, divalent or trivalent ions of A and B chains were detected in the products of all base lengths under the enzyme addition conditions, confirming the progress of the reaction.

[0132] The peak area value of the substrate under each reaction condition was calculated by HPLC, and the remaining rate of the substrate was calculated using the following formula. Residual rate (%) = (sum of substrate peak areas under enzyme addition conditions) / sum of peak areas of substrate in negative control) x 100

[0133] Products consisting of 11-mer complementary segments tended to have a higher residual substrate percentage than products consisting of 12-mer complementary segments.

[0134] [Table 13]

[0135] [Table 14]

[0136] [Example 16] Reaction with high concentration substrate The reaction rate of modified oligonucleotide formation in the presence of higher substrate concentrations was compared at each pH. The target product strands of the reaction were designated as strand A and strand B. The sequences of the target product and the synthesized substrate fragments are shown in Table 15, and the combinations of the four fragments are shown in Figure 16.

[0137] The composition of the reaction solution was 1.78 μg / mL T4 RNA ligase 2 (New England Biolabs), 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, and 50 mM Tris-HCl (pH 7.0-9.0) was used as a buffer. Oligonucleotide fragments were added as substrates to a final concentration of 10 μM, 300 μM, 500 μM, or 1000 μM, and the reaction was carried out in a volume of 40 μL. The reaction was carried out at 25°C using a thermal cycler, and the reaction was stopped by sampling after 15 minutes or 1 hour and adding EDTA to a final concentration of 10 mM. The ligation product contained in the reaction solution was analyzed by HPLC under the conditions described in Example 5, and the production rate was calculated from the total concentration of A chain and B chain. The reaction progress was confirmed even at a substrate concentration of 300 μM or more, and at these concentrations, a high reaction rate was shown at pH 8.0 and 8.5.

[0138] [Table 15]

[0139] [Example 17] Effect of adding surfactant The reaction rate of modified oligonucleotide production by adding a surfactant was evaluated. The sequences of the target product and the synthesized substrate fragments are shown in Table 15, and the combination of the four fragments is shown in Figure 16. The reaction solution consisted of 1.78 μg / mL T4 RNA ligase 2 (New England Biolabs), 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, 50 mM Tris-HCl (pH 7.5), and a surfactant of 0.1% final concentration of TritonX-100. As substrates, oligonucleotide fragments were added to a final concentration of 20 μM, and the reaction was carried out in a volume of 40 μL. In the evaluation, three conditions were compared: the enzyme solution was diluted to 17.8 μg / mL with storage buffer (10 mM Tris-HCl, 50 mM KCl, 35 mM ammonium sulfate, 0.1 mM dithiothreitol, 0.1 mM EDTA, 50% glycerol, pH 7.5) and then added to the reaction solution in a 1 / 10 amount (control condition); the enzyme solution was diluted to 17.8 μg / mL with storage buffer and then added to a reaction solution containing a final concentration of 0.1% TritonX-100 in a 1 / 10 amount (test condition 1); and the enzyme solution was diluted to 17.8 μg / mL with storage buffer containing 0.1% TritonX-100 and then added to a reaction solution containing 0.09% TritonX-100 in a 1 / 10 amount (test condition 2, final TritonX-100 concentration 0.1%). The reaction was carried out at 25°C using a thermal cycler, and after 4 hours, the reaction was stopped by sampling and adding EDTA to a final concentration of 10 mM. The ligation product contained in the reaction solution was analyzed by HPLC under the conditions described in Example 5, and the concentrations of A strand and B strand were calculated. Higher concentrations of A-chain and B-chain products were observed in test conditions 1 and 2 compared to the control condition.

[0140] [Example 18] Comparison of impurity selection depending on the base length of the product Reactions of different base lengths were carried out for the substrate and product, and impurities contained in the substrate oligonucleotide fragment and the solution after the enzyme reaction were analyzed. The target product strands of the reaction were designated as strand A and strand B. The sequences of the target product and the synthesized substrate fragments are shown in Table 16, and the combinations of the four fragments are shown in Figure 17.

[0141] The composition of the reaction solution was 8.9 μg / mL T4 RNA ligase 2 (New England Biolabs), 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5 for the reaction using modified oligonucleotides. The composition of the reaction solution was 22.0 μg / mL T7 DNA ligase (New England Biolabs), 50 mM Tris-HCl, 2 mM MgCl2, 1 mM dithiothreitol, 400 μM ATP, pH 7.5 for the reaction using DNA. Four oligonucleotide fragments were added as substrates to a final concentration of 50 μM, and the reaction was carried out in a volume of 30 μL. The reaction was carried out at 25° C. using a thermal cycler, and the reaction was stopped after 8 hours by adding EDTA to a final concentration of 12.5 mM. The reaction solution was analyzed by HPLC and LC-TOF / MS under the conditions described in Example 5 to confirm the progress of the intended reaction.

[0142] The content of impurities (N±1mer) relative to the product of the desired structure was calculated from the mass spectrometry results obtained based on the method described in the previous literature (Roussis et al., Journal of Chromatogr A. 2019;1584:106-114.). In addition, the substrate oligonucleotide solution subjected to the reaction was also analyzed by LC-TOF / MS, and the content of impurities (N±1mer) relative to the substrate was calculated.

[0143] From the values ​​calculated above, the remaining impurity rate (%) was calculated for each of the A and B chains in each reaction using the following formula. Impurity remaining rate (%) = (Ratio of N±1 mer to the target product in the reaction solution) / (Ratio of N±1 mer to the substrate in the substrate solution) × 100

[0144] The results are shown in Table 17. In the reaction producing an oligonucleic acid having a length of 28 bases, the remaining rate of impurities (N±1 mer) was 86% or more, whereas in the reaction producing an oligonucleic acid having a length of 25 bases or less, it was 23 to 59%.

[0145] [Table 16]

[0146] [Table 17] [Industrial Applicability]

[0147] INDUSTRIAL APPLICABILITY The present invention is useful for producing modified oligonucleotides (eg, siRNAs, heteroduplex oligonucleotides, etc.) that can be used in products such as nucleic acid medicines.

Claims

1. 1. A method for producing a modified oligonucleotide comprising a complementary portion of 11-27 bases in length, comprising: The method includes treating a total of four or more oligonucleotide starting fragments in the presence of an oligonucleotide ligase to produce the modified oligonucleotide; The total of four or more oligonucleotide raw material fragments correspond to the oligonucleotide raw material fragments obtained by dividing the modified oligonucleotide at fragment linkages that satisfy the following conditions (i) to (v): (i) there is at least one fragment linker on each strand of the complementary portion, and there are a total of two or more fragment linkers in the modified oligonucleotide; (ii) when the modified oligonucleotide is split at the fragment junction, a protruding end is formed in the complementary portion, and the protruding end is 1 to 10 bases in length; (iii) at least one oligonucleotide starting fragment comprises a modified nucleotide; (iv) four of the four or more oligonucleotide raw material fragments contain a complementary portion having a length of 5 to 25 bases; and (v) The total length of the bases corresponding to each strand of the complementary portion of the oligonucleotide starting fragment is 11 to 27 bases.

2. The method according to claim 1, wherein the overhanging end in (ii) is 2 to 6 bases long.

3. 3. The method according to claim 1 or 2, wherein the portions of the complementary portions of the four oligonucleotide starting fragments defined in (iv) other than the protruding ends are 4 to 16 bases long.

4. The method according to any one of claims 1 to 3, wherein the oligonucleotide ligase is an RNA ligase.

5. The method of claim 4, wherein the oligonucleotide ligase is a double-stranded RNA ligase.

6. The method according to claim 5 , wherein the double-stranded RNA ligase is an RNA ligase of the Rnl2 family or the Rnl5 family.

7. The method of any one of claims 1 to 6, wherein the modified oligonucleotide comprises a modified nucleotide residue.

8. The method according to claim 7, wherein the modified nucleotide residue is a 1', 2', 3', or 4' chemically modified nucleotide residue, a 5'- or 3'-phosphate group modified nucleotide residue, a bridged modified nucleotide residue, a carrier-added modified nucleotide residue, or a sugar backbone substituted nucleotide residue.

9. The modified nucleotide residue is i) the 1', 2', 3', or 4' position is C 1~6 Alkyloxy C 1~6 Alkylene, —O—C 1~6 Alkyl, —O—C 6~14 Aryl, -C-aryl, halogen atom, -O-C 1~6 Alkyl N-amide C 1~6 Alkylene, —O—C 1~6 Alkyl-(C 1~6 Alkyl-)amino-C 1~6 Alkylene, or -O-amino C 1~6 1', 2', 3', or 4' chemically modified nucleotide residues substituted with alkyl (e.g., -O-aminopropyl, -O-AP); ii) a hydroxyl group optionally substituted with a protecting group, —O—P(S)(OH) 2 , -NH-Ρ(O)(OH) 2 , or -NH-P(S)(OH) 2 a 5'- or 3'-phosphate modified nucleotide residue substituted with iii) the 2' and 4' sites are 2'-O-C 1~6 Alkylene-4', 2'-O-ethylene-4', 2'-O-methyl substituted methylene-4', 2'-O-C 1~6 Alkylene -O-C 1~6 Alkylene-4',2'-O-N(R)-C 1~6 Alkylene-4' (wherein R represents methyl, hydrogen atom or benzyl), 2'-N(R)-C(O)-4', 2'-NH-C 1~6 Alkylene-4' or 2'-C 1~6 or the 3' and 5' positions are substituted with 3'-C 1~6 an alkylene-5' substituted bridged modified nucleotide residue; or iv) a hexitol nucleic acid (HNA) residue, a cyclohexenyl nucleic acid (CeNA) residue, or a morpholino nucleic acid (PMO) residue The method of claim 8, wherein

10. The method according to any one of claims 1 to 9, wherein the total molar ratio of any two oligonucleotide starting fragments selected from the oligonucleotide starting fragments is 0.5 to 2.

11. The method according to any one of claims 1 to 10, wherein the oligonucleotide raw material fragment is treated under a monovalent cation salt concentration of 10 mM or less.

12. The method according to any one of claims 1 to 11, wherein the mixed solution of oligonucleotide raw material fragments is not placed at a high temperature and then cooled down prior to said processing.

13. The method of any one of claims 1 to 12, wherein production of impurities of the modified oligonucleotide is inhibited.

14. The method of any one of claims 1 to 13, further comprising purifying the modified oligonucleotide.

Citation Information

Patent Citations

  • Novel processes for the production of oligonucleotides

    US20180023122A1